Vividion Therapeutics Promotes Jean Bemis to Chief Operating Officer
Vividion Therapeutics, Inc. is excited to announce the promotion of Jean Bemis to the role of Chief Operating Officer. This move comes as the clinical-stage biopharmaceutical company continues its mission to unlock high-value, traditionally undruggable targets and develop innovative small molecule precision therapeutics.
Jean Bemis has proven herself as an invaluable leader within the biotech field, bringing a wealth of experience from various reputable organizations. She joined Vividion in 2017 as the Head of Alliance Management before being appointed Senior Vice President of R&D Operations and Alliances in 2022.
Under the leadership of CEO Aleksandra Rizo, who praised Jean’s contributions, it is clear that her influence has helped shape Vividion's transition to a clinical-stage company. She has played a significant role in advancing the company’s innovative pipeline of oncology and immunology assets.
Before her tenure at Vividion, Jean was integral to new company formations such as Gene Sciences, Inc., Rodin Therapeutics, and Warp Drive Bio, where she focused on program management and drug development initiatives. Additionally, her experience includes pivotal roles at Amgen, GSK, and Wyeth, where she drove numerous projects forward.
As Jean reflects on her journey, she expresses gratitude for supporting Vividion's growth into a clinical-stage organization focusing on groundbreaking candidates for difficult-to-treat cancers and immune disorders. With a pipeline that includes two oncology assets currently in clinical studies, she shares enthusiasm for the future, noting the recent acquisition of Tavros Therapeutics and the anticipated expansion of chemoproteomics capabilities.
Vividion, as a wholly owned and independently operated subsidiary of Bayer AG, is positioning itself at the forefront of biopharmaceutical innovation.
About Vividion Therapeutics
Vividion Therapeutics, Incorporated is a biopharmaceutical company committed to unlocking traditionally undruggable targets using advanced discovery technologies. By identifying hundreds of functional pockets on validated protein targets, Vividion has developed a proprietary covalent chemistry library that interacts selectively with these targets. This unique approach supports the advancement of a diversified portfolio aimed at treating complex cancers and immune disorders.
Vividion’s proprietary chemoproteomic platform has paved the way for creating highly selective small molecules. This platform empowers the company with the capability to push forward the development of innovative therapeutics targeting high-value areas in oncology and immunology.
About Bayer AG
Bayer AG operates as a global enterprise in the life science sectors of health care and nutrition. With an emphasis on sustainable development and creating a positive impact for people and the planet, Bayer’s products and services are aligned to tackle pressing global challenges. In fiscal 2023, Bayer employed about 100,000 individuals and generated sales amounting to 47.6 billion euros, showcasing its commitment to innovation and trust through its reputable brand.
Frequently Asked Questions
What was the significance of Jean Bemis's promotion?
Jean Bemis's promotion to COO signifies Vividion's commitment to strengthening its leadership as it advances transformative therapies for challenging health conditions.
What has Jean Bemis accomplished at Vividion?
Jean has significantly contributed to team expansion, clinical transitions, and the advancement of Vividion’s transformative therapeutic pipeline.
How is Vividion Therapeutics approaching drug development?
Vividion employs novel discovery technologies to identify and develop small molecule therapeutics for traditionally undruggable targets in oncology and immunology.
What is Vividion’s connection to Bayer AG?
Vividion Therapeutics operates as an independently run subsidiary of Bayer AG, leveraging Bayer’s foothold in the life sciences to enhance its research and innovation.
What future initiatives does Vividion have?
Vividion plans to expand its research capabilities through the acquisition of Tavros Therapeutics and by enhancing its chemoproteomics platform in a new facility.
